Nexsen Clears ISO 13485 Stage 1 Audit Unlocking Path to Global Market Access

Nexsen clears Stage 1 ISO 13485 audit as QMS foundation takes shape

Nexsen Limited has completed its Stage 1 ISO 13485 audit, conducted by BSI, a globally recognised certification body. The Nexsen ISO 13485 QMS milestone represents a foundational step toward full certification, supporting clinical validation, regulatory submissions, and future commercial manufacturing for the company’s diagnostic pipeline, including its lead product StrepSure.

The successful audit confirms that Nexsen’s Quality Management System (QMS) is appropriately structured to support clinical and regulatory programmes across multiple regions. The company is now progressing toward its Stage 2 certification audit, with ISO 13485 certification and alignment with Medical Device Single Audit Program (MDSAP) requirements remaining on track.

For medical device investors, this procedural milestone is critical infrastructure. Without ISO 13485 certification, companies cannot access major global markets or secure regulatory approvals. Clearing Stage 1 signals the quality framework is structurally sound for the commercialisation pathway ahead.

What is ISO 13485 and why does it matter for medical device investors?

ISO 13485 is the international standard for medical device quality management systems. Regulatory bodies globally require this certification before approving devices for commercial sale. The certification process involves two stages: Stage 1 reviews documentation and system readiness, while Stage 2 assesses practical implementation and compliance.

The MDSAP framework allows medical device companies to complete a single audit that satisfies regulatory requirements across multiple jurisdictions, including the United States, Canada, Australia, Japan, and Brazil. This streamlined approach reduces both time and cost compared to managing separate audits for each market.

Without ISO 13485 certification, medical device companies are locked out of revenue-generating markets. This educational context helps investors understand why this milestone, though procedural, represents essential infrastructure for future commercial activities.

Global market access unlocked through single audit framework

Nexsen’s QMS supports three distinct geographic pathways:

• United States and MDSAP-participating jurisdictions: Alignment with MDSAP requirements enables efficient regulatory inspections and multi-market access through a single audit framework, supporting expansion across the US, Canada, Australia, Japan, and Brazil.
• Australia and Asia-Pacific markets: ISO 13485 certification underpins regulatory approval, clinical validation activities, and early commercial deployment across the region.
• Future European expansion: ISO 13485 certification forms a foundational requirement for regulatory approval and market entry across European jurisdictions.

The MDSAP alignment is expected to reduce regulatory complexity significantly. Rather than navigating separate inspection regimes for each jurisdiction, Nexsen can leverage a single audit framework, accelerating potential market entry timelines and reducing operational costs associated with multi-jurisdictional compliance.

Management perspective on quality infrastructure

Mark Muzzin, Managing Director

“Establishing a robust Quality Management System is a critical step in translating diagnostic technologies from development through to clinical validation and commercialisation. The successful completion of our Stage 1 audit confirms that our QMS is appropriately structured to support our clinical and regulatory programs, including the advancement of StrepSure across multiple regions.”

The statement reinforces that the quality foundation now in place supports the StrepSure advancement across multiple regions, while also providing infrastructure for the broader diagnostic pipeline.

Next steps toward certification

Nexsen is progressing toward its Stage 2 certification audit, with ISO 13485 certification and MDSAP alignment remaining on track. While the announcement does not provide specific timelines, completion of Stage 2 will represent full certification, enabling regulatory submissions and commercial manufacturing activities to proceed.

Stage 2 certification will mark the transition from structural readiness to verified implementation, a critical threshold for accessing global markets.

Nexsen’s diagnostic pipeline in context

Nexsen is a rapid point-of-care diagnostics company focused on delivering lab-grade results for conditions traditionally dependent on delayed laboratory testing. The QMS infrastructure supports not just StrepSure but the entire diagnostic pipeline, creating optionality as multiple products advance through development.

1. GBS Rapid Sensor (marketed as StrepSure): Rapid point-of-care diagnostic for detecting Group B Streptococcus, addressing a critical unmet need in maternal health.
2. Acute Kidney Injury diagnostics: Rapid kidney function diagnostic for a condition affecting more than 850 million people globally and underserved by slow, lab-based testing.
3. Chronic Kidney Disease diagnostics: Additional kidney function diagnostic targeting the same underserved global patient population.
4. Broader pipeline: Further diagnostics in development across human health, ag-tech, and biosecurity sectors.

The quality management framework established through ISO 13485 certification provides the regulatory and commercial infrastructure required to advance each of these diagnostic technologies from development through to market deployment. For investors, this represents a de-risked pathway to multiple revenue streams as the pipeline matures.

Want the Next Healthcare Breakthrough in Your Inbox?

Join 20,000+ investors receiving FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements and expert coverage the moment news breaks.